MAS1L and portal hypertension: Contrary to this, we found that in the PPVL rat model of non-cirrhotic portal hypertension, blockade of neither MasR nor MrgD, whose mesenteric expression was unaltered, affected portal pressure or MAP, suggesting that unlike in cirrhotic portal hypertension, the alternate RAS is not a key mediator of splanchnic vasodilatation in this condition.